© 1997 by European Society of Cardiology
Copyright © 1997, European Society of Cardiology
Sulfonylurea derivatives in cardiovascular research and in cardiovascular patients
aDepartment of Clinical and Experimental Cardiology, Academic Medical Center, University of Amsterdam, PO BOX 22700, 1100 DE Amsterdam, Netherlands
bThe Heart-Lung Institute, University of Utrecht, Utrecht, Netherlands
* Corresponding author. Tel.: +31 20 5663265; fax: +31 20 6975458.
Sulfonylurea derivatives are hypoglycemic drugs frequently used in the treatment of non-insulin-dependent diabetes mellitus (NIDDM). In the β-cell sulfonylureas act by blocking ATP-sensitive potassium channels (K.ATP channels). In several organ systems, including the cardiovascular system, sulfonylurea receptors and functional K.ATP channels have been identified. In the heart their role is not clear; an endogenous cardioprotective effect has been suggested. There is no doubt that K.ATP channels are effectively blocked by sulfonylureas. In the last decade sulfonylureas have been widely used as a pharmacological tool in experimental (cardiac) research. Blockade of K.ATP channels is the proposed cellular mechanism of action for all sulfonylurea-related effects. However, other membrane currents are affected as well. In addition, myocardial metabolism is modified by sulfonylurea pretreatment. Hence, it should seriously be questioned whether these drugs are suitable in assessing involvement of cardiac K.ATP channels in, for example, ischemia-related events. The detrimental effects of sulfonylureas in experimental studies on myocardial ischemia have led to speculation whether the widespread use of these drugs in patients with NIDDM, most often suffering from accompanying ischemic heart disease, should be reconsidered. However, a review of the clinical literature reveals that the most consistent finding is a lower incidence of ventricular arrhythmias associated with the use of glibenclamide, while no excess mortality has been shown for this agent in NIDDM with ischemic heart disease. Despite some direct effects on systemic and coronary vasculature, there are, at present, no firm clinical data on the basis of which sulfonylurea derivatives should be withheld from the cardiac patient.
KEYWORDS Sulfonylureas; Diabetes; Potassium channel, ATP-sensitive; Arrhythmias; Myocardial infarction; Myocardial ischemia
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  T.-M. Lee, M.-S. Lin, and N.-C. Chang Effect of pravastatin on sympathetic reinnervation in postinfarcted rats Am J Physiol Heart Circ Physiol, December 1, 2007; 293(6): H3617 - H3626. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T.-M. Lee, M.-S. Lin, C.-H. Tsai, and N.-C. Chang Effect of pravastatin on left ventricular mass in the two-kidney, one-clip hypertensive rats Am J Physiol Heart Circ Physiol, December 1, 2006; 291(6): H2705 - H2713. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Brigadeau, C. Kouakam, D. Klug, C. Marquie, A. Duhamel, F. Mizon-Gerard, D. Lacroix, and S. Kacet Clinical predictors and prognostic significance of electrical storm in patients with implantable cardioverter defibrillators Eur. Heart J., March 2, 2006; 27(6): 700 - 707. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Saito, T. Sato, T. Miki, S. Seino, and H. Nakaya Role of ATP-sensitive K+ channels in electrophysiological alterations during myocardial ischemia: a study using Kir6.2-null mice Am J Physiol Heart Circ Physiol, January 1, 2005; 288(1): H352 - H357. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. M Mohan and D. J Paterson Activation of sulphonylurea-sensitive channels and the NO-cGMP pathway decreases the heart rate response to sympathetic nerve stimulation Cardiovasc Res, July 1, 2000; 47(1): 81 - 89. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. A. Remme and A. A.M Wilde A new, sympathetic look at KATP channels in the heart Cardiovasc Res, July 1, 1999; 43(1): 17 - 19. [Full Text] [PDF]
|
|
|
|
|
|
K. Oe, B. Sperlagh, E. Santha, I. Matko, H. Nagashima, F. F Foldes, and E.S. Vizi Modulation of norepinephrine release by ATP-dependent K+-channel activators and inhibitors in guinea-pig and human isolated right atrium Cardiovasc Res, July 1, 1999; 43(1): 125 - 134. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. E. Schotborgh and A. A.M. Wilde ATP-Sensitive Potassium Channel Openers and Blockers in the Cardiovascular System: Physiology, Pharmacology, and Clinical Effects Seminars in Cardiothoracic and Vascular Anesthesia, September 1, 1998; 2(3): 243 - 255. [Abstract] [PDF]
|
|
|
|
|
|
F.C Huvers, P.W de Leeuw, C.H.A de Haan, A.J.H.M Houben, C Buijs, and N.C Schaper The enhanced pressor response in type 2 diabetes is not based upon a generalized increase in vascular responsiveness Cardiovasc Res, April 1, 1998; 38(1): 206 - 214. [Abstract] [Full Text] [PDF]
|
|